Literature DB >> 2454667

The new basement membrane antigen recognized by the monoclonal antibody GB3 is a large size glycoprotein: modulation of its expression by retinoic acid.

P Verrando1, A Pisani, J P Ortonne.   

Abstract

Further biochemical investigations on the hemidesmosome-associated epidermal basement membrane component recognized by the monoclonal antibody GB3 are presented in this study. We previously found that the expression of this constituent is impaired in a severe genodermatosis termed lethal junctional epidermolysis bullosa. We demonstrate now that this factor is a very large glycoprotein (apparent molecular weight, 600 kDa) made up of polypeptides in the range of 93.5 to 150 kDa, and containing N-linked oligosaccharide chains. Both endo-beta-N-acetylglucosaminidases and neuraminidase hydrolysis, as well as concanavalin A binding experiments were performed on the GB3 radioimmunoprecipitated polypeptides from cultured human keratinocytes. They showed that the antigen subunits probably bear both 'high-mannose' and 'complex' type glycosidic chains. The chronic exposure of cultured human keratinocytes to retinoic acid (10(-8) to 10(-6) M) resulted in no apparent changes in the overall bulk of these glycosidic chains, but a dose-dependent increase of synthesis and secretion of the antigen was observed. A relative induction factor of 4 was obtained in cultures treated with 10(-6) M retinoic acid. This induction was also observed morphologically by indirect immunofluorescence at the basement membrane zone from cultured human keratinocytes grown on dead de-epidermized dermis. These results further emphasize the influence of glycoproteins in cell-cell and cell-substratum attachment. Furthermore, the ability to modulate this antigen may be relevant for the understanding of the molecular defect involved in lethal junctional epidermolysis bullosa.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454667     DOI: 10.1016/0005-2736(88)90273-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Molecular genetics of the cutaneous basement membrane zone. Perspectives on epidermolysis bullosa and other blistering skin diseases.

Authors:  J Uitto; A M Christiano
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

Review 2.  Epidermolysis bullosa: hereditary skin fragility diseases as paradigms in cell biology.

Authors:  R A Eady; M G Dunnill
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

3.  Hypoxia increases human keratinocyte motility on connective tissue.

Authors:  E A O'Toole; M P Marinkovich; C L Peavey; M R Amieva; H Furthmayr; T A Mustoe; D T Woodley
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 4.  Defining the role of laminin-332 in carcinoma.

Authors:  Cherise M Guess; Vito Quaranta
Journal:  Matrix Biol       Date:  2009-08-15       Impact factor: 11.583

5.  Herlitz junctional epidermolysis bullosa keratinocytes display heterogeneous defects of nicein/kalinin gene expression.

Authors:  C Baudoin; C Miquel; C Blanchet-Bardon; C Gambini; G Meneguzzi; J P Ortonne
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

6.  alpha3beta1 Integrin is required for normal development of the epidermal basement membrane.

Authors:  C M DiPersio; K M Hodivala-Dilke; R Jaenisch; J A Kreidberg; R O Hynes
Journal:  J Cell Biol       Date:  1997-05-05       Impact factor: 10.539

7.  Extent of laminin-5 assembly and secretion effect junctional epidermolysis bullosa phenotype.

Authors:  C Matsui; P Pereira; C K Wang; C F Nelson; T Kutzkey; C Lanigan; D Woodley; M Morohashi; E A Welsh; W K Hoeffler
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

8.  Sole expression of laminin gamma 2 chain in invading tumor cells and its association with stromal fibrosis in lung adenocarcinomas.

Authors:  Y Kagesato; H Mizushima; N Koshikawa; H Kitamura; H Hayashi; N Ogawa; M Tsukuda; K Miyazaki
Journal:  Jpn J Cancer Res       Date:  2001-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.